Skip to content
  1. Home/
  2. Latest news/
  3. What you need to know about Johnson & Johnson’s 2023 second-quarter earnings
A cartoon of workers contemplating graphs

What you need to know about Johnson & Johnson’s 2023 second-quarter earnings

Check out this infographic breakdown of the company’s second-quarter 2023 performance, with key highlights from its Pharmaceutical, MedTech and Consumer Health businesses.

Quarterly earnings banner

This morning, Johnson & Johnson shared its second-quarter performance.

Since its founding in 1886, the company has grown to become the world’s largest, most diversified healthcare products company, with more than 150,000 employees across the globe working every day to help change the trajectory of health for humanity.

“Johnson & Johnson delivered strong second quarter results. We executed against our long-term business strategy by attaining key clinical and regulatory milestones in our Pharmaceutical and MedTech businesses and made considerable progress toward the separation of Kenvue,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson. “These advancements provide a strong foundation for the long-term growth of the company and are reflective of the dedication of our colleagues around the world. We will continue to invest in innovation that brings transformational treatments to patients and delivers long-term value to shareholders.”

For more details about the company’s 2023 second-quarter results, and to read a message from Chairman of the Board and Chief Executive Officer Joaquin Duato, here’s an infographic that highlights key stats.


An infographic about Q2 2023 earnings

Johnson & Johnson’s 2023 2nd-Quarter Earnings

Read the earnings press release, which includes full financial data for the second quarter of 2023.

Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

More from Johnson & Johnson

Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD

Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.

The future of immunology

Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.

Using your own cells to fight cancer

Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson is moving this cutting-edge therapy forward.